摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-bromo-2,3-dihydrobenzo[1,4]dioxine

中文名称
——
中文别名
——
英文名称
6-bromo-2,3-dihydrobenzo[1,4]dioxine
英文别名
2-(2-Bromocyclohexa-1,3-dien-1-yl)-1,4-dioxine
6-bromo-2,3-dihydrobenzo[1,4]dioxine化学式
CAS
——
化学式
C10H9BrO2
mdl
——
分子量
241.084
InChiKey
BCRBZSNCCWGHLY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    2-氨基-4-氟苯酚6-bromo-2,3-dihydrobenzo[1,4]dioxine9-methyl-9H-fluorene-9-carbonyl chloridedichloro(cycloocta-1,5-diene)palladium (II)1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 tri tert-butylphosphoniumtetrafluoroborate 、 N-甲基二环己基胺甲烷磺酸 作用下, 以 1,4-二氧六环 为溶剂, 反应 19.0h, 以85%的产率得到2-(2,3-dihydrobenzo[1,4]dioxin-6-yl)-5-fluorobenzoxazole
    参考文献:
    名称:
    通过钯催化的芳基溴化物和乙烯基溴化物的氨基羰基化反应,获得2-(辛基)芳基和2-苯乙烯基苯并恶唑
    摘要:
    报道了一种顺序一锅法合成2-(杂)芳基或2-苯乙烯基苯并恶唑的方法,该方法分别从芳基和乙烯基溴开始,涉及以2-氨基酚为亲核试剂的初始氨基羰基化反应,然后是酸介导的环闭合以生成杂环。该方法显示了中等范围到优异产量的广泛底物范围,可用于13 C同位素标记。最后,将此羰基化方案应用于潜在的阿尔茨海默氏菌斑粘合剂和选择性PPAR拮抗剂的合成,包括用13 C-一氧化碳进行位点特异性标记。
    DOI:
    10.1021/acs.orglett.5b00642
点击查看最新优质反应信息

文献信息

  • Inhibitors of CYP 17
    申请人:BOCK Mark G.
    公开号:US20100331326A1
    公开(公告)日:2010-12-30
    The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R 53 , R 54 , p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C 17,20 -lyase inhibitors.
    本发明提供了式(I)和(II)的化合物,或其药用可接受的盐, 其中R 53 ,R 54 ,p,q和n如本文所述定义。本发明的化合物被发现作为17α-羟化酶/C 17,20 -裂解酶抑制剂是有用的。
  • Diphenylethylene compounds and uses thereof
    申请人:Muller W. George
    公开号:US20050107339A1
    公开(公告)日:2005-05-19
    The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more Diphenylethylene Compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more Diphenylethylene Compounds. The present invention further relates to articles of manufacture and kits comprising one or more Diphenylethylene Compounds.
    本发明涉及二苯乙烯化合物和包含二苯乙烯化合物的组合物。本发明还涉及通过向需要的受试者施用一种或多种二苯乙烯化合物来预防或治疗各种疾病和紊乱的方法。具体而言,该发明涉及通过向需要的受试者施用一种或多种二苯乙烯化合物来预防或治疗癌症或炎症性紊乱的方法。本发明还涉及包含一种或多种二苯乙烯化合物的制品和工具包。
  • [EN] SULFAMATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS<br/>[FR] DÉRIVÉS DE SULFAMATE ET DE SULFAMIDE POUR LE TRAITEMENT DE L'ÉPILEPSIE ET DE TROUBLES APPARENTÉS
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2006007435A1
    公开(公告)日:2006-01-19
    The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical composlons containing them and their use in the treatment of epilepsy and related disorders.
    本发明涉及新型磺胺酰胺和磺酸酯衍生物,包含它们的药物组合物以及它们在治疗癫痫和相关疾病中的用途。
  • USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR LOWERING LIPIDS AND LOWERING BLOOD GLUCOSE LEVELS
    申请人:Smith-Swintosky L. Virginia
    公开号:US20070155821A1
    公开(公告)日:2007-07-05
    The present invention is a method for the glucose related disorders and lipid related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) or formula (II) as herein defined. The present invention is further directed to methods of treatment comprising co-therapy with an anti-diabetic agent, and anti-lipid agent and/or an anti-obesity agent.
    本发明涉及一种治疗葡萄糖相关疾病和脂质相关疾病的方法,包括向需要的受试者施用一种或多种新型苯并杂环磺胺生物的治疗有效量,其化学结构如公式(I)或公式(II)所定义。本发明还涉及治疗方法,包括与抗糖尿病药物、抗脂质药物和/或抗肥胖药物联合治疗。
  • USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF DEPRESSION
    申请人:Smith-Swintosky L. Virginia
    公开号:US20070155827A1
    公开(公告)日:2007-07-05
    The present invention is a method for the treatment of depression comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to a method for the treatment of depression, which includes mono-therapy and alternatively, co-therapy with at least one antidepressant.
    本发明涉及一种治疗抑郁症的方法,包括向需要的受试者施用一种或多种新型苯并杂环磺酰胺衍生物的治疗有效量,其化学式为(I)和(II)。本发明涉及一种治疗抑郁症的方法,包括单独治疗和/或与至少一种抗抑郁药物联合治疗。
查看更多

同类化合物

环丙羧酸,2-(羟甲基)-3-甲基-,甲基酯,(1S,2R,3R)- 丙酸,2-甲氧基-,1-(5,6-二氢-1,4-二噁烷-2-基)-2-甲氧基-1-丙烯基酯 三丁基(5,6-二氢-1,4-二恶英-2-基)-锡烷 [1,2]二恶英并[4,3-b]吡啶 5-乙酰基-3,6-二甲基-1,4-二恶英-2(3H)-酮 5-(5,6-二氢-1,4-二氧杂环己烯-2-基)-1,3,4-噁二唑-2-胺 5,6-二氢-[1,4]二恶英-2-羧酸 5,6-二氢-1,4-二恶英-2-甲醛 5,6-二氢-1,4-二恶英-2-甲酰氯 3-甲基-5,6-二氢-1,4-二恶英-2-羧酸 2-甲基-5,6-二氢-1,4-氧硫杂环己烷-3-羧酸4,4-二氧化物 2-甲基-5,6-二氢-1,4-二恶英 2-(5,6-二氢-1,4-二氧-2-基)-4,4,5,5-四甲基-1,3,2-二氧杂硼烷 2-(5,6-二氢-1,3-二硫环戊并[4,5-B][1,4]二烷-2-亚基)-5,6-二氢-1,3-二硫环戊并[4,5-B][1,4]二烷 2,3-二氢-5,6-二甲基-1,4-二恶英 2,2,2-三氟-1-(3-甲基-5,6-二氢-1,4-二恶英-2-基)乙酮 1H,5H-环戊二烯并[5,6][1,4]二恶英并[2,3-d]咪唑 1,4-二氧杂-2-己烯 1,4-二恶英-2-甲酰氯,5,6-二氢-3-甲基-(9CI) 1,4-二恶英 2-(2,2,2-trifluoro-1-trifluoromethyl-ethylidene)-3,6-dihydro-2H-pyran ethylenedioxodiselenadithiafulvalene (E)-N-benzyl-2-(2-(furan-2-yl)vinyl)-4,5-dihydrofuran-3-carboxamide 4-(2-(5,6-Dihydro-[1,3]dithiolo[4,5-b][1,4]dioxin-2-ylidene)-1,3-dithiol-4-yl)pyridine 1,3,4,5-Tetrakis-(trifluoromethyl)-6,7-dimethyl-2-oxabicyclo<3.2.0>hepta-3,6-dien 2,4-Bis-(hexafluoroisopropyliden)-1,3-dioxolan 6,9-Dichlorospiro[2,4-dihydro-[1,4]dioxepino[2,3-d]pyridazine-3,1'-cyclopentane] 3-acetoxymethyl-(3ar,7at)-hexahydro-benzooxazole-2-thione 1-(2-methyl-5,6-dihydro-[1,4]oxathiin-3-yl)-ethanone 2,3-dihydro-9H-cyclohept<1,2-b>-1,4-oxathiin 4-[5-(4,5-Bis-methylselanyl-[1,3]dithiol-2-ylidene)-[1,3]dithiolo[4,5-d][1,3]dithiol-2-ylidene]-tetrahydro-pyran 1-(5,6-Dihydro-1,4-dioxin-2-yl)-3-methyl-1-butanone 2H-arsinino[4,3-b]pyran 2,2-Diaethyl-3,4,5,6-tetrachlor-2H-pyran (5-Chloromethyl-4,5-dihydro-furan-3-yl)-phosphonic acid dibutyl ester (5,6-dihydro-p-dioxin-2-yl)phosphonic acid 2-(2(5H)-furanylidene)-5-methyltetrahydrofuran 2,4-dichloro-4-dioxolan-2-ylidene-3-oxobutanenitrile 4,5-dichloro-4',5'-ethylenedioxytetrathiafulvalene 4,4,6-trimethyl-2-(2,4,4,6-tetramethyl-[1,3]oxazinan-2-ylmethyl)-5,6-dihydro-4H-[1,3]oxazine 4',5'-dimethyl-EDO-TTF 2-<2-(1,4-dioxenyl)>-1-propene 4,5-ethylenedioxy-4'-iodotetrathiafulvalene N-(1,2,2,2-tetrachloroethyl)-5,6-dihydro-2-methyl-1,4-oxathiin-3-carboxamide (2-(5,6-dihydro-[1,3]dithiolo[4,5-b][1,4]dioxin-2-ylidene)-1,3-dithiol-4-yl)trimethylstannane 2-(2,4,6,8-tetrathia-10,13-diselenatricyclo[7.4.0.03,7]trideca-1(9),3(7)-dien-5-ylidene)-5,6-dihydro-[1,3]dithiolo[4,5-b][1,4]dioxine 1-(5,6-Dihydro-[1,4]dioxin-2-yl)-2-methyl-propan-1-one 4,5-diiodo-4',5'-ethylenedioxytetrathiafulvalene Ethylenedioxymethylenediselenotetrathiafulvalene